Paris Metro bans David Hockney exhibition poster because artist is holding cigarette - Exclusive: David Hockney condemns ‘dismal’ decision taken by Paris Metro over poster for biggest ever Hockney exh ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Search for the best digital art software and the best drawing software and you'll find plenty of options, all offering a broad array of brushes, design tools, and sharing possibilities to get your ...

Today, he travels frequently, stopping in Berlin; Cambridge, England, where his sixteen-year-old son, Lao, his only child, attends school; and Montemor-o-Novo, a town in the countryside of ...

Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price for people who are uninsured or insured on commercial plans that don't cover the obesity drug. Through ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest ...

Novo announced results from a new weight loss drug that failed to meet expectations. Despite the results, the company is still in a strong position to continue leading the weight loss space. Novo ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

Shares of Novo Nordisk dropped Monday after the company reported that its next-generation obesity drug produced weight loss results in diabetes patients that fell short of investors ...